Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: john david martin who wrote (162)	11/29/1997 10:04:00 PM
From: Don W Stone	Respond to of 507

No one is forecasting. Dr Mates, President of NVX, has been quoted recently as saying that she expects approval by year end. If you take a few minutes to review the lastest 10Q you will get the idea that the company is certainly expecting it anytime now. As to PATIENCE it has proven to be a very good virtue for some of the long term holders of the stock.( to some a triple, to many a double), particularly if one was able to add to their position on weakness. However, it is anybodies guess as to what the short term will bring following FDA approval for their DTaP. The stock should certainly be trading at a higher level. Long term? The consensus on annual growth for the next 5 years according to Zacks is 75%. Earnings estimates of $1.00 plus for '98, around $2.00 for '99 and upwards of $5.00 for 2000. However I think we can assume that all analyst projections will be updated during the 1st quarter of '98 and from that point on those projections will be factored into the price of the stock in some way. AT what multiple? We'll see. PATIENCE. :-}